Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Systemic Lupus Erythematosus (SLE) Patients
Maha Shokry Mohammed Abdulhafez;
Abstract
S
ystemic lupus erythematosus (SLE) is one of the most investigated autoimmune disorders, characterized by a systemic inflammatory reaction. It affects nearly all vital organs and tissues and is characterized by a wide spectrum of clinical signs and symptoms. The diagnosis of SLE is based on thorough clinical assessment of the patient. The disease course is fluctuating, characterized by acute and often severe exacerbations. Several scoring systems have been validated to measure disease activity (Griffiths et al. 2005); however, no objective laboratory marker has been identified that can reliably be used for the detection of ongoing inflammation in correlation with clinical symptoms in SLE.
Circulating soluble urokinase plasminogen activator receptor (suPAR) has emerged as a potential marker of inflammation and disease severity, and an outcome predictor in several disparate conditions. This study was done to evaluate suPAR as a marker of disease activity and organ damage in SLE.
Our study done on 50 Egyptian SLE patients and 40 healthy controls, with female to male ratio 9:1.
suPAR values are higher in SLE patients than in healthy controls. The assessment of inflammation is of special importance in the timely detection and treatment of potentially dangerous flares of SLE. So far, ESR has been the most widely used parameter to describe the inflammatory reaction in SLE. However, suPAR is a more stable and reliable parameter for the detection of inflammation than ESR, which might be influenced by several other factors (such as anemia). In further contrast with ESR, suPAR might be especially suitable for identifying patients with active disease, since suPAR values are elevated in patients with high disease activity in comparison with moderate disease activity lupus patients and those with inactive disease. Hence, suPAR represents an objective clinical marker that can reliably be used for the detection of ongoing inflammation with respect to disease severity in SLE.
ystemic lupus erythematosus (SLE) is one of the most investigated autoimmune disorders, characterized by a systemic inflammatory reaction. It affects nearly all vital organs and tissues and is characterized by a wide spectrum of clinical signs and symptoms. The diagnosis of SLE is based on thorough clinical assessment of the patient. The disease course is fluctuating, characterized by acute and often severe exacerbations. Several scoring systems have been validated to measure disease activity (Griffiths et al. 2005); however, no objective laboratory marker has been identified that can reliably be used for the detection of ongoing inflammation in correlation with clinical symptoms in SLE.
Circulating soluble urokinase plasminogen activator receptor (suPAR) has emerged as a potential marker of inflammation and disease severity, and an outcome predictor in several disparate conditions. This study was done to evaluate suPAR as a marker of disease activity and organ damage in SLE.
Our study done on 50 Egyptian SLE patients and 40 healthy controls, with female to male ratio 9:1.
suPAR values are higher in SLE patients than in healthy controls. The assessment of inflammation is of special importance in the timely detection and treatment of potentially dangerous flares of SLE. So far, ESR has been the most widely used parameter to describe the inflammatory reaction in SLE. However, suPAR is a more stable and reliable parameter for the detection of inflammation than ESR, which might be influenced by several other factors (such as anemia). In further contrast with ESR, suPAR might be especially suitable for identifying patients with active disease, since suPAR values are elevated in patients with high disease activity in comparison with moderate disease activity lupus patients and those with inactive disease. Hence, suPAR represents an objective clinical marker that can reliably be used for the detection of ongoing inflammation with respect to disease severity in SLE.
Other data
| Title | Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Systemic Lupus Erythematosus (SLE) Patients | Other Titles | معدل مستقبلات اليوروكينيز بلازمينوجين المنشط فى البلازما فى مرضى الذئبة الحمراء | Authors | Maha Shokry Mohammed Abdulhafez | Issue Date | 2015 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.